DS-103
DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis[1].
Product Specifications
UNSPSC
12352005
Target
HDAC; Parasite
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection
Smiles
O=C(N(CC1=CC=C(C=C1)C(NNCC)=O)CC(NCC2=CC=CC=C2)=O)C3=CC=C(C=C3)N(C)C
Molecular Formula
C28H33N5O3
Molecular Weight
487.59
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HDAC6; HDAC8
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
IgA Secretory Component (SC05), CF740 conjugate, 0.1mg/mL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Eosinophil Peroxidase (AHE-1), CF594 conjugate, 0.1mg/mL
